Le Lézard
Classified in: Health, Business
Subjects: CON, OTC

Encompass Compliance Corporation (ENCC) and Madison Avenue Drug Testing Sign a Channel Sales Agreement


CHARLOTTE, North Carolina, March 16, 2017 /PRNewswire/ --

Encompass Compliance Corp. (OTC PINK:ENCC) announces a channel sales agreement with Madison Avenue Drug Testing.

Encompass Compliance Corp. is the most comprehensive provider of workplace drug and alcohol testing compliance services, with over 30 years of experience. We are dedicated to providing employers with the tools necessary to mitigate regulatory and compliance risk. Our solutions provide organizations with up-to-date policies, a comprehensive resource center and real-time monitoring for drug and alcohol testing orders.

Madison Avenue Drug Testing (http://madisonavenueproducts.com) is a premier provider of drug testing products to corporations throughout the U.S. They provide products that test for: THC, alcohol, cocaine, amphetamines, methamphetamines, opiates, benzodiazepines, propoxyphene, PCP, oxycodone, morphine, ecstasy, methadone, buprenorphine, barbiturates, ketamine, K2, tramadol, ETG. "As a supplier of drug testing products to over 3,000 companies, they are a natural fit to provide our Risk Shield Compliance services to their customers," says Encompass CEO, Richard Sharp.

Madison Avenue Drug Testing CEO Keith Devine says, "We feel extremely fortunate to be selected by Encompass Inc. as a channel partner. Combining the best legal minds in the business with our diverse clientele, instills confidence in our customers that they are provided the most comprehensive state specific compliance solutions available."

There will be joint marketing activities such as webinars, regular mailings and updates on a regular basis to Madison Avenue Drug Testing Customers.

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered "forward-looking" under the provisions of the Private Securities Litigation Reform Act of 1995. Statements generally identified by phrases such as the Company or its management "believes," "expects," "forecasts," "estimates," or other words or phrases are forward-looking.


For further information, contact:
Richard Sharp
866-328-7487
[email protected]
https://www.encompinc.com/

SOURCE Encompass Compliance Corp.


These press releases may also interest you

at 10:30
Electrosurgery Market in terms of revenue was estimated to be worth $6.9 billion in 2024 and is poised to reach $9.4 billion by 2029, growing at a CAGR of 6.4% from 2024 to 2029 according to a new report by MarketsandMarketstm. The market for...

at 10:20
Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI). The goal of this Phase 2 SPI-1005...

at 10:13
FDNA Inc, the leader in the early detection of rare genetic diseases, and Genome Medical, the nation's leading telehealth provider of genetic services, have partnered to empower parents to detect potential developmental, neurological and...

at 10:11
Most parents are used to hearing pediatricians discourage screen time for kids, but during National Safe Sun Week doctors are actually asking for more ? sunscreen time that is! Keeping skin protected by increasing summer "screen time" is a major...

at 10:02
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Instituto Mário Penna is live on the SOPHiA DDMtm Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna...

at 10:01
Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, announces the results of a groundbreaking independent study led by Mayo Clinic and presented at Digestive Disease Week...



News published on and distributed by: